OTC · Biotechnology

Baudax Bio, Inc. (BXRXQ) Stock

$0.00 OTC: BXRXQ Healthcare

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders.

Valuation

MetricValue
Price$0.00
Market Cap$4359
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$-941.30
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE245.83%
ROA-114.93%
ROCE497.14%
Gross Margin-5700.00%
Operating Margin-5700.00%
Net Margin-5900.00%
Debt/Equity-0.29
Current Ratio0.07

Annual Financials (USD)

Metric20182019202020212022
Revenue$0$0$0$1.0M$1.0M
Operating Profit$-74.0M$-33.0M$-75.0M$-19.0M$-57.0M
Net Profit$-74.0M$-33.0M$-76.0M$-20.0M$-59.0M
EPS$-11361.35$-4872.07$-5714.80$-361.16$-177.30
Op Margin——-15169.6%-1759.8%-4477.0%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$35.0M$54.0M$69.0M$53.0M$10.0M
Total Liabilities$103.0M$71.0M$84.0M$40.0M$34.0M
Cash$0$18.0M$30.0M$16.0M$5.0M
Borrowings$0$1.0M$10.0M$9.0M$7.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-60.0M$-50.0M$-44.0M$-49.0M$-28.0M
Investing Cash Flow$-7.0M$-3.0M$-1.0M$0$0
Financing Cash Flow$63.0M$69.0M$2.0M$4.0M$-1.0M
Net Cash Flow$0$18.0M$13.0M$-14.0M$-11.0M
Free Cash Flow$-63.0M$-52.0M$-45.0M$-49.0M$-28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.06
FCF Yield-638059.19%
Quick Ratio0.30
Interest Coverage0.00
Return 1Y900.00%
Return 3Y-99.98%
Return 5Y-100.00%

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Sittner & Nelson, LLC12025-09-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Baudax Bio, Inc.

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2015 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Baudax Bio, Inc. (BXRXQ) stock trades at $0.00 with a market capitalization of $4359. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Baudax Bio, Inc. generates a return on equity (ROE) of 245.83% — well above the market average, a sign of a high-quality business, return on capital employed of 497.14%, an operating margin of -5700.00%, a net profit margin of -5900.00%.

Official website: www.baudaxbio.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides